Archives of Epidemiology & Public Health Research(AEPHR)
ISSN: 2833-4353 | DOI: 10.33140/AEPHR
Impact Factor: 1.98
Abdel-Hady El-Gilany
Professor, Department of Public Health and Preventive Medicine, Faculty of Medicine,Mansoura, Mansoura University, Egypt
Publications
-
Research Article
Real Data on Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 Versus Remdesivir or Favipiravir in Hospitalized COVID Cases
Author(s): Hatem Elalfy*, Tarek Besheer, Ahmed El-Mesery, Abdel-Hady El-Gilany, Mohamed Alegezy, Mahmoud Abdelaziz Soliman, Mohamed Elegezy, Hossam Zaghloul, Mustafa Ahmed Mohamed Neamatallah, Nermin Y Abo El Kheir, Maii Saad, Doaa Khedr, Adel El-Badrawy, Ahmed Ezzat Helal, Mahmoud El-Bendary and Tamer Elhadidy
Background: The pandemic of COVID-19 has forced the health system to incorporate many antiviral drugs into medical field applications. Researchers have started clinical trials to assess the effectiveness of many virus-targeting medications due to the pressing need for a safe and efficient treatment. Aim: This study examined the the real world data describe effectiveness of nitazoxanide, ribavirin, and ivermectin plus zinc in comparison to those taking remdesivir or favipiravir treatment. Subject and Methods: Patients inclusion start after approval from Mansoura IRB at April with code number RP.20.05.69. This non-randomized open label-controlled trial included 108 hospitalized patients receiving treatment classified into 3 groups: NRIZ group, favipiravir group, and remdesivir group. They all verified the case with a.. Read More»